Esperion Therapeutics ESPR reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Esperion Therapeutics beat estimated earnings by 12.9%, reporting an EPS of $-0.81 versus an estimate of $-0.93.
Revenue was up $4.57 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.12 which was followed by a 1.7% drop in the share price the next day.
Here's a look at Esperion Therapeutics's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | -0.93 | -1.04 | -2.27 | -2.79 |
EPS Actual | -1.05 | -0.93 | -1.77 | -2.62 |
Revenue Estimate | 18.71M | 15.39M | 14.47M | 12.85M |
Revenue Actual | 18.84M | 18.84M | 15.40M | 14.41M |
To track all earnings releases for Esperion Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.